Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Cash from Investing Activities (2016 - 2025)

Ocular Therapeutix (OCUL) has 13 years of Cash from Investing Activities data on record, last reported at -$2.8 million in Q4 2025.

  • For Q4 2025, Cash from Investing Activities fell 1305.45% year-over-year to -$2.8 million; the TTM value through Dec 2025 reached -$11.9 million, down 822.36%, while the annual FY2025 figure was -$11.9 million, 822.36% down from the prior year.
  • Cash from Investing Activities reached -$2.8 million in Q4 2025 per OCUL's latest filing, up from -$6.0 million in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at -$89000.0 in Q3 2024 and bottomed at -$6.0 million in Q3 2025.
  • Average Cash from Investing Activities over 5 years is -$1.2 million, with a median of -$563000.0 recorded in 2021.
  • Peak YoY movement for Cash from Investing Activities: surged 92.45% in 2024, then tumbled 6633.71% in 2025.
  • A 5-year view of Cash from Investing Activities shows it stood at -$631000.0 in 2021, then plummeted by 240.73% to -$2.2 million in 2022, then skyrocketed by 78.65% to -$459000.0 in 2023, then surged by 55.99% to -$202000.0 in 2024, then crashed by 1305.45% to -$2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Investing Activities were -$2.8 million in Q4 2025, -$6.0 million in Q3 2025, and -$1.1 million in Q2 2025.